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Abstract. The present study introduces a modified melt-electrospinning (MES) method 
for fabricating the melt-electrospun fibers (MSFs) of a poorly water-soluble drug and 
carrier polymer. The MES of poorly water-soluble model drug indomethacin (IND) and 
hydrophilic carrier polymer, Soluplus® (SOL) were prepared at a 1:3 drug-polymer 
weight ratio. Water was used as an external plasticizer to regulate a MES processing 
temperature and to improve fiber formation. The fiber size, surface morphology, physical 
solid state, drug-polymer (carrier) interactions, thermal and chemical stability and 
dissolution behavior of MSFs were investigated. Solid state nuclear magnetic resonance 
spectroscopy (NMR) was used to measure T1(1H), and the domain size of IND in MSFs 
(25-100 nm) was calculated from these results. Solid-state and thermal analysis 
confirmed the presence of amorphous solid dispersions of IND and SOL. IND was found 
to be chemically stable during an entire MES process. Only small drug content variability 
of different MSF batches was detected with high performace liquid chromatography 
(HPLC). Given findings were verified with the liquid NMR spectroscopy. The 
dissolution of MSFs was significantly faster than that of physical mixtures (PMs) or pure 
drug. The enhanced dissolution of MSFs was caused by high surface area, amorphous 
state of the drug and solubilizing properties of the carrier polymer (SOL). 
 
 
 
 
Keywords: Melt electrospinning, Melt-spun fibers, Poorly water-soluble drug, 
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1. Introduction 
 
Formulation development of oral solid dosage forms for poorly water-soluble drugs is a 
major challenge to the pharmaceutical industry (Di et al., 2009). The well-known 
formulation approaches to tackle this challenge include e.g., salt formation, 
micronisation, co-crystals, solid dispersions (SDs), surfactants, inclusion complexes with 
cyclodextrins, and lipid-based systems (Vasconcelos et al., 2007; Williams et al., 2013). 
Another novel emerging method that enables to formulate poorly water-soluble drugs is 
electrospinning (ES) of active pharmaceutical ingredient (API) together with an 
amphiphilic polymer. 
 
ES, also called as “electrostatic drawing”, is a versatile nano- and microfabrication 
method, in which a high voltage is used to create an electrically charged continuous liquid 
jet of a polymer solution. As given jet is electrostatically drawn onto a grounded 
collector, the solvent evaporates or the molten polymer solidifies and the fibers are 
formed. Melt-electrospinning (MES) is a thermal modification of ES where instead of 
polymer solution a molten polymer is used as a substrate. MES has a number of 
advantages over a conventional solution-based ES: (1) the use of organic solvent(s) can 
be avoided; (2) the yield is exceptionally high (often 100%); (3) the size of fibers is 
uniform (diameter  5%), and (4) MES can be readily extended to three dimensional (3D) 
direct writing mode for preparing tissue engineering scaffolds (analogue of 3D printing). 
Despite of these significant advantages, a major limiting factor for MES is perhaps a high 
processing temperature, which means that only thermostable compounds can be 
processed (Balogh et al., 2015; Bhardwaj and Kundu, 2010). In addition, the diameter of 
the MES fibers is generally at a sub-micron or micron-scale instead of nano-scale (Dalton 
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et al., 2006; Hutmacher and Dalton, 2011). Moreover, MES can be performed with rather 
limited number of biocompatible water-soluble polymers in the melt (Bhardwaj and 
Kundu, 2010). 
 
The most significant parameters affecting melt-electrospun fiber (MSFs) formation and 
diameter are feeding rate, applied voltage, temperature, polymer conductivity, polymer 
molecular weight, distance between the spinneret and collector, collector type and 
moving speed (Brown et al., 2016). The feeding rate should support the Taylor cone 
formation with following fiber drawing. If the rate is too slow, Taylor cone does not 
evolve and if too fast it might start pulsating affecting the fiber diameter. Like in 
conventional ES, voltage is used to draw the fiber towards collector. Voltage also 
stabilizes the fiber jet in case of MES. Too high voltage can lead to process instabilities 
(whipping). The distance between the spinneret and collector is usually in a centimetre 
range (Dalton et al., 2007), and it needs to be long enough to allow the fiber to solidify. 
However, changes in voltage might be needed to avoid the whipping. In case of 
specialized methods, such as near-field ES (Sun et al., 2006) and electro-hydrodynamic 
jet plotting (Wei and Dong, 2013), the distance between collector and the spinneret could 
be in a micron range. Temperature affects the process through changing polymer 
viscosity (higher polymer weight leads to higher viscosity). If the melt is too viscous, 
high processing temperatures are needed that might lead to thermal decomposition. 
 
It is possible to reduce the MES temperature by adding plasticizers (Balogh et al., 2014). 
Plasticizers are usually non-volatile compounds with small molecular weight that are 
incorporated in a polymer matrix to lower its rigidity and improve the processing of the 
polymer. The addition of the plasticizer to the polymer lowers the glass transition 
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temperature, elastic modulus and viscosity of the melt of the mixture (Lim and Hoag, 
2013). Unfortunately the lowered glass transition temperature can compromize the 
physical stability of the resultant SD (Craig et al., 1999). Thus, it would be preferable to 
use volatile plasticizers that desorb during or after processing. As the glass transition 
temperature of water is approximately at -135°C (Haque and Roos, 2004; Heljo et al., 
2012) and it is vaporized at temperatures where MES is usually carried out, it could be a 
suitable candidate for a given purpose. 
 
Temperature also affects the polymer drug miscibility during processing. There are 
several methods that can be used to estimate the drug polymer miscibility or the solubility 
of the drug in polymer at ambient conditions. Flory-Huggins theory, Gordon-Taylor 
equation, Hansen solubility parameter and Brostow Chiu Kalogeras Vassilikou-Dova 
(BCKV) equations have been used among others (Bochmann et al., 2016; Craig et al., 
1999; Djuris et al., 2013; Marsac et al., 2009). Drug-polymer miscibility has also a crucial 
role in physical stability of the SDs. It is expected that the system would be physically 
stable if the drug is miscible with polymer at given conditions. For example, Bochmann 
et al. (2016) have calculated the solubility of our drug indomethacin (IND) in carrier 
polymer SOL at different temperatures using BCKV equation. They discovered that the 
solubility of IND is 26% (w/w) at 25°C, and that they are miscible in molten state 
(Bochmann et al., 2016).  
 
To date, less than 1% of electrospinning literature is dedicated to the solvent-free 
approaches (Dalton, 2017). The first paper describing melt-spun filament formation from 
polypropylene and polyethylene was published in 1981 (Larrondo and St. John Manley, 
1981). Polymers such as polycaprolactone (PCL) (Brown et al., 2011), 
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polyethylenglycol-polycaprolactone block polymer (PEG-b-PCL) (Dalton et al., 2008), 
polypropylene (PP) (Haigh et al., 2017) and poly(ethylene-co-vinyl) alcohol (EVAL) 
(Ogata et al., 2007) have been mostly investigated for tissue engineering rather than drug 
delivery purposes. The pharmaceutical applications of MES are still scarce, but in the 
recent years the interest towards present technique has steadily increased. Nagy et al. 
(2013) and Balogh et al. (2014) have successfully developed fast dissolving fibrous 
formulations for poorly water-soluble carvedilol using hydrophilic Eudragit® E and 
different plasticizers by utilizising MES and melt-blowing, respectively (Balogh et al., 
2014; Nagy et al., 2013). Lian & Meng (2017) obtained modified drug release with 
daunorubicin-PCL loaded fibrous membranes prepared by MES (Lian and Meng, 2017). 
 
Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer is a 
recently introduced amphiphilic polymer intended for pharmaceutical applications 
(BASF, 2010). It is also know as Soluplus® (SOL). SOL was originally developed as a 
carrier material for hot-melt extrusion (HME) and granulation processes, but due to its 
unique properties (thermal behaviour, solubilizing properties, binding effects, etc.), it has 
also been tested in other pharmaceutical manufacturing processes (Lust et al., 2013, 
2015; Semjonov et al., 2017). 
 
The primary goals of the present study were to investigate a modified MES for fabricating 
the MSFs intended for improving the dissolution rate of a poorly water-soluble drug 
(IND as a model drug), and to gain understanding of the physical solid-state changes, 
drug-carrier polymer interactions, and dissolution behaviour associated with the present 
MSFs. In addition, the role and effects of absorbed water on the MES process were 
investigated. 
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2. Materials and methods 
 
2.1 Materials 
 
Indomethacin [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid] in a γ 
polymorphic form (Acros, United Kingdom) was used as a poorly water-soluble model 
drug. Soluplus® (SOL), polyvinyl caprolactam-polyvinyl acetate polyethylene glycol 
graft copolymer (BASF SE Pharma Ingredients & Services, Ludwigshafen, Germany) 
was used as a carrier polymer. 
 
2.2 Methods 
 
2.2.1  Preparation of physical mixtures (PMs) 
 
Raw materials were passed through a 150-m size sieve. The physical mixtures (PMs) 
were prepared by mixing SOL with IND in mortar with pestle as described in our 
previous paper (Semjonov et al., 2017). The batch size of each PM was 6.0 g. The PM1 
consisted of crystalline γ-IND and SOL (1:3). The PM2 consisted of amorphous IND 
prepared by quench cooling of a melt and SOL at a 1:3 weight ratio. The PM3 was 
obtained storing a PM1 on a Petri dish at high relative humidity (~90%) for 72 hours. 
The PMs 1 and 2 were used as the reference samples and PM3 was used in the MES 
experiments for MSF preparation.  
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2.2.2  Melt electrospinning (MES) 
 
Prior to MES, the PM3 was stored at 90% RH and at an ambient room temperature for 
72 hours. The MSFs were prepared with an ESR200RD system (NanoNC Co. Ltd., Seoul, 
Republic of Korea) equipped with a special MES spinneret (metal syringe with attached 
needle) coupled with a thermostated oil bath circulator (NanoNC Co. Ltd., Seoul, 
Republic of Korea) (Fig. 1). The MES of drug-loaded fibers was performed at 180 C 
and at a voltage of 5-10 kV (Model HV30 high-voltage power supply unit). The angle of 
spinneret was set at 25, and the distance between a spinneret and fiber collector was 5.0 
cm. The collector was grounded. The process was driven by build-in pressure from water 
evaporation, hence without the need for applied feeding rate. Fibers were colleted on a 
rotating drum (15 rpm). The MSFs of pure carrier polymer (SOL) was used as a reference 
to drug-loaded fibers. Prepared MSFs were stored in a desiccator at 15% RH (23 C). 
MSFs were further processed by grinding them in mortar with pestle. The obtained 
powder was used for analysis and dissolution testing. 
 
 
Figure 1. Schematic illustration of a melt electrospinning (MES) device with a heating 
system based on oil circulating through the jacket placed around the metal syringe. Arrow 
points out circulating heated oil and the direction of the collector movement. The symbol 
P designates build-in pressure from water evaporation. 
 
2.2.3  Thermal analysis 
 
A DSC 4000 differential scanning calorimeter (Perkin Elmer Ltd., Shelton, CT, USA) 
was used for the thermal analysis of MSF samples in an aluminum pans with pinholes in 
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a lid and under a dry nitrogen flow. The samples (2-8 mg) were heated from 20 to 200 
°C at a rate of 10 °C/min. The DSC system was calibrated with indium. 
 
Thermogravimetric analysis (TGA) was performed with a NETZSCH STA 449 F3 
Jupiter®, (NETZSCH- Gerätebau GmbH, Germany) simultaneous thermal analyzer in 
order to study a mass loss and thermal degradation of the samples upon heating. Oxygen 
nitrogen mixture (in the ratio of 20 to 80) was used as a purge gas at the flow rate of 60 
ml/min. Samples (25-35 mg) were placed on a corundum sample holders. The sample 
was heated from 20 °C to 350 °C at the rate of 10 °C/min and held isothermally at 350 
°C for 10 min. Data were processed with NETZSCH Proteus® Software for Thermal 
Analysis. Temperatures are given as onset-points unless otherwise mentioned. 
 
2.2.4 High-Performance Liquid Chromatography (HPLC) 
 
The total amount and chemical stability of IND in MSF (three different batches, n=8) 
was determined by means of HPLC (254 nm) using slightly modified European 
Pharmacopoeia (Eur. Ph) method for IND. HPLC system (Shimadzu Prominence LC20 
with PDA detector SPD-M20A) controlled by software LCsolution was used. Standard 
of IND (~0.15 mg/mL) was dissolved in acetonitrile:water solution (1:1). The column 
Phenomenex Luna2 C18 was used with the flow rate of 1.0 mL/min and injection volume 
of 10 µL at the temperature of 50 °C. Following mobile phases were used: (A) a 0.3% 
(m/V) solution of acetic acid in water, (B) a solution containing 0.3% (m/V) acetic acid 
and 0.7% (m/V) of water in acetonitrile. Retention time of IND was about 8 min. HPLC 
was also used to confirm the results of drug release from MSF obtained by UV-Vis 
spectrophotometer. 
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2.2.5  Scanning electron microscopy (SEM)      
 
A high-resolution scanning electron microscope (SEM) (Zeiss EVO MA 15, Carl Zeiss 
Microscopy GmBH, Germany) was used for imaging the surface morphology and 
diameter of MSFs. The samples were imaged without coating in argon atmosphere under 
high pressure at different magnifications. Furthermore, the surface morphology and 
porosity (internal voids within fibers and voids/pores on the fiber surface) were analysed 
using SEM micrographs and ImageJ software was used for calculating the pore size. 
 
2.2.6  X-ray powder diffraction (XRPD)       
 
The XRPD patterns of rotating samples were collected using Bruker D8 Advance 
diffractometer (Bruker AXS GmbH, Germany) using Cu Kα1 radiation (λ=1.5418 Å, 40 
kV and 40 mA). Data were gathered in theta–theta geometry in the range of 5°–35° 2θ, 
(with the step size of 0.0195° 2θ) and with a LynxEye positive sensitive detector. 
 
2.2.7  Fourier transform infrared spectroscopy (FTIR) 
 
Fourier transform infrared spectroscopy (FTIR) of samples was performed with IR 
Prestige-21 Spectrophotometer (Schimadzu Corp., Kyoto, Japan) and Specac Golden 
Gate Single Reflection ATR crystal (Specac Ltd., Orpington, UK). Operating range was 
4000–600 cm-1. The final spectrum was the mean of 60 scans and each sample was 
measured in triplicate.  
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2.2.8  Nuclear magnetic resonance (NMR) spectroscopy    
 
1H and 13C FT-NMR-spectra in CDCl3 (Eur-isotop 99.80% containing 0.03% TMS) 
solution together with 13C CP-MAS spectra in solid state were recorded using Bruker 
Avance III 500 MHz spectrometer (Bruker, UK Limited, United Kingdom). 13C-CP-
MAS-spectra were recorded for the pure materials as well as for PM1 and MSFs using 
10 kHz rotation, 3 ms contact time and 10 s delay between pulses. The 1H-spectra of IND 
and SOL together with their PM1 and MSFs were recorded with the materials dissolved 
in deuterochloroform. Solution spectra were recorded in 5 mm glass tubes and solid state 
spectra in 4 mm rotors. All spectra were recorded at 23 °C. 
 
2.2.9  Dissolution test 
 
The dissolution tests were carried out in a Distek Dissolution system 2100B (Distek, Inc., 
North Brunswick, New Jersey, USA). The United States Pharmacopeia (USP) paddle 
method (Type 2) was used for dissolution testing. The samples (n = 3) were analyzed 
using an UV-Vis spectrophotometer (Specord® 200 Plus, Analytik Jena AG, Germany) 
at 370 nm. It was confirmed that neither SOL nor MSFs from pure SOL showed any 
absorption at 370 nm. The samples were manually withdrawn at fixed time intervals (10 
min, 20 min, 30 min, 60 min, 120 min) and filtered (0.45 µm membrane) before analysis. 
Degasified buffer solution (pH = 6.8) with a total volume of 500 ml at 37.0 ± 0.5 °C was 
used as a dissolution medium. The paddle rotation speed was set at 100 rpm. All tests 
were perfomed in triplicate.  
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2.2.10  Data analysis 
 
The fiber size of MSFs (n=30-50) was measured with ImageJ (version. 1.50i). Data are 
expressed as a mean ± SD. Statistical analysis was performed with a 2-tailed unpaired t-
test using MS Excel Software 2010. The level of significance was set at p < 0.05 (denoted 
on the figures by *). Origin Pro 8.5 (Origin Lab Corporation) was used to draw the 
figures. 
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3. Results and discussion 
3.1   Design and fabrication of melt-electrospun fibers  
 
MES is a continuous bottom-up technique for preparing polymeric fibrous systems at a 
nano- or micro-scale. MES does not use any organic solvents, and consequently, no 
subsequent drying phase is needed. We determined the critical MES parameters 
necessary for the fabrication of the MSFs of the present drug (IND) and carrier polymer 
(SOL) (i.e., temperature, voltage, distance between a melt spinneret and collector, and 
the angle of spinneret, speed of rotating collector). The feeding rate was calculated from 
the time taken for the sample to be electrospun. As it took approximately 30 minutes to 
spin the 6 gram sample, the feeding rate was 12 g/h.  
 
At first, PM1 was electrospun directly without pre-storing it at high RH. Due to high 
viscocity of the melt, it was necessary to increase the temperature of the process to 220 
°C and specific smell and colour changes indicated the degradation of the drug. Pre-
storing the samples at high humidity (above 90% RH) in dessiccator prior MES 
experiments was used in order to plasticize the PM1. The water sorption in the PM 
samples was verified by collecting the NIR spectra from the samples stored at different 
humidities (Appendix) and measuring TGA (s.f. paragraph 3.2 “Thermal analysis”). Pre-
storing the samples at high humidity enabled to lower the processing temperature of MES 
by 40 °C (to 180 °C). Hence, the addition of plasticizer (in our case water) was of critical 
importance. In addition, water vapor heated up to 180°C created additional pressure that 
probably helped to overcome the high viscosity of the polymer melt. 
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3.2 Thermal analysis 
 
Similarly to widely used hot-melt extrusion (HME) also in MES the materials are 
subjected to a short-term high temperature and pressure during the process. These 
conditions can cause the chemical degradation of drug, polymer or both. According to 
the literature, the thermal decomposition of IND is a one-step phenomenon within the 
temperature range of 236-338 °C (Tita et al., 2009a). The IND has a good safety margin 
for thermal processing at lower temperatures. According to Forster et al. (2001), the 
chemical stability of IND in PVP/IND dispersions at different weight ratios (1:1 and 4:1) 
after HME at 170 °C was good, since only less than 1% of drug was decomposed. Melt 
extrusion of acrylic polymers/IND (30% drug concentration) showed that IND is 
chemically stable after exposure to high temperature (140 °C) (Zhu et al., 2006). SOL is 
thermally stable up to 220°C showing no changes in chemical composition or degree of 
polymerization (BASF, 2010; Kolter et al., 2012). 
 
The results of thermogravimetric analysis (TGA) of pure materials and PMs are depicted 
in Fig. 2A. Weight loss of the samples up to 150 °C was assigned to water evaporation 
upon heating. Given values were used to estimate the amount of water absorbed by SOL 
and PMs. The SOL contained 2.4% and the PM1 contained 1.6% of water by weight. 
After storage at high relative humidity (90%) the PM3 contained 7.4% of water by 
weight. IND was found to be a thermally stable compound at the temperature that was 
used for MES (only 0.1% of weight loss at 180 °C was detected). The thermal 
degradation of IND and SOL started at 197.1 °C and 218.2 °C, respectively. According 
to the literature, the thermal degradation of IND occurs approximately at 236 to 338 °C 
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(with Tmax 314 °C) (Tita et al., 2009b). The present results are in agreement with those 
reported in the literature, where a 2.5% weight loss of SOL was detected at low 
temperatures, and the degradation of the material started approximately at 250 °C (Kolter 
et al., 2012). In summary, TGA results suggest that MES performed at 180 °C is a non-
destructive process and does not cause (or causes only minimal) thermal degradation for 
the present materials. A long-term exposition of materials to MES process, however, will 
most likely result in thermal degradation of the materials. 
 
The TGA results were in line with the DSC results, where γ-IND showed a sharp melting 
endotherm at 161.8 °C (without any water desorption), and SOL showed a broad water 
evaporation endotherm until 76.3 °C (indicating also a substantial amount of water in the 
samples) (Fig. 2B). The DSC thermographs of PM1 showed a broad water evaporation 
endotherm derived from SOL within PMs and a broad fusion endotherm of γ-IND into 
SOL starting at 115.7 °C. The fusion endotherm ended with a minor sharp endotherm at 
160.1 °C, which was attributed to the melting of residual γ-IND. The PM2, containing 
amorphous IND and SOL at the weight ratio 1:3 (drug:polymer) presented the Tg of IND 
at 50.6 °C and a water evaporation endotherm. In addition, a small exothermic peak was 
recorded for PM2 at 83.8 °C, and it was assigned to the crystallization of IND. The onset 
temperature of the subsequent fusion endotherm for recrystallized IND was recorded at 
107.0 °C. The PM3 (stored at high RH 90%) thermogram mirrored the results of PM1. 
As expected, the thermal behavior of PMs revealed the behavior of the pure materials 
alone (Fig. 2B). The DSC thermograph of MSF indicates the formation of amorphous 
SD, since no signs of recrystallization and melting endotherm of IND were detected, 
which might indicate at least partial mixing of a drug in a molten polymer (Fig. 2B). 
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Figure 2. Thermogravimetric analysis (TGA) (A) and differential scanning calorimetry 
(DSC) thermograms (B) of starting materials, physical mixtures (PMs) and melt-
electrospun fibers (MSF). Key: γ-IND – indomethacin, SOL - Soluplus®, PM1 – the 
physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 (drug:polymer), 
PM2 – the physical mixture of amorphous IND and SOL at the weight ratio 1:3 
(drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-electrospun fibers 
prepared from PM3. The actual process temperature of MES (180 C) is indicated with 
a solid line in the figure. 
 
3.3 Indomethacin content assessment within MSFs 
 
In our study, the total drug content of MSFs was assayed/verified by HPLC. Three 
different MES batches were analysed in duplicate or triplicate (theoretical drug content 
was 25%). The following drug contentents for different MSF batches were measured: 
23.2  0.15% (n=3) for batch 1; 23.8  0.6% (n=3) for batch 2; and 23.5  0.4% (n=2) 
for batch 3. These values are in close proximity to the theoretical drug content values 
confirming that the present MES process is stable and reproducible resulting in small 
drug content variation. Given results are in a good agreement with the data presented in 
literature. It is known that IND (Tita et al., 2009a) and SOL (Kolter et al., 2012) are both 
stable at the conditions they were presented during the MES.  
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3.4 Fiber size, shape and surface morphology 
 
The fiber size and morphology of drug-loaded MSFs (IND and SOL at the weight ratio 
of 1:3) and the corresponding blank MSFs are presented in Fig. 3. The diameter of drug 
loaded MSFs varied from 300 to 400 µm and the diameter of blank MSFs ranged from 
200 µm to 400 µm. As reported elsewhere, the diameter of MSF can vary even from 270 
nm (i.e., nano-scale) to 500 µm (micro-scale) (Dalton et al., 2006; Lyons et al., 2004). 
Such a wide size range option in fiber diameters shows the flexibility of MES. In our 
study, the large micro-scale size of MSFs could be explained by high molecular weight 
of SOL (90 000 – 140 000 g/mol) (BASF, 2010). According to the literature, the 
molecular weight of a thermal carrier polymer is a critical factor determining the final 
fiber diameter in MES (Lyons et al., 2004).  
 
The surface morphology of the present MSFs (Fig. 3A) was smooth without any voids 
or pores, but clearly shrunken and billowy for the whole fiber area. This could be 
explained by a thermal shock induced by the temperature difference during MES when 
the fibers are produced and collected. The shrinking was more pronounced with blank 
MSFs (Fig. 3B), thus showing a higher polymer chain mobility compared to the drug 
loaded MSF. It is well known that higher surface area results in higher dissolution rate 
(Noyes and Whitney, 1897). Hence the major advantage of shrunken and billowy MSFs 
compared to the smooth fibers is larger specific surface area, and thus their dissolution 
rate should be faster compared to the smooth surfaced fibers/particles. Also, the 
supersaturation ratio has been shown to be an important factor governing the 
passive transportation of poorly-water soluble drugs from supersaturated solutions 
(Borbás et al., 2016) 
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Figure 3. The SEM images of (A1) intact melt-electrospun fibers (MSF) of γ-IND and 
SOL at the weight ratio of 1:3 (drug to polymer), (A2) the corresponding ground MSFs, 
(B1) blank MSFs, and (B2) the corresponding ground blank MSFs. Key: γ-IND – 
indomethacin, SOL – Soluplus®. 
 
The SEM image of the drug loaded MSFs cross-section (Fig. 3A1) shows a non-uniform 
structure of the fiber. At some places, the fibers are hollow and at others they do not have 
any inner voids at all. The cross section of blank fiber (as shown in Fig. 3B1) consisted 
of primarily intact solid surface with very small voids. The difference in the morphology 
of drug-loaded and blank MSFs could be related to the different molecular mobility and 
rigidity of the IND containing SOL and pure SOL during MES process. As mentioned 
earlier, the instability of a MES process could also partially explain the formation of 
MSFs with such a complicated structure. Fig. 3 shows also the SEM images of drug-
loaded (A2) and blank (B2) MSFs in a powder form after grinding. The partially hollow 
structure of the original MSFs can still be seen even after grinding (Fig. 3A2). These 
cavities are evidently the former water vapor channels inside a fiber matrix, and they are 
formed as water evaporates from the matrix or extrudate during fiber formation 
(Miladinov and Hanna, 1999). 
 
SEM micrographs together with ImageJ software was used for calculating the size of the 
resultant water vapor channels in our materials. The average pore size for the intact drug-
loaded and blank MSFs were 28.2 m (ranging from 0.5 to 301.4 μm) and 13.3 m 
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(ranging from 3.0 to 59.6 μm), respectively. The average pore size for the ground drug-
loaded and ground blank MSF particles was 32.5 μm (ranging from 8.4 to 65 μm) and 
40.8 μm (ranging from 2.4 to 109 μm), respectively. The average pore sizes for the drug-
loaded MSFs and ground drug loaded MSF powder were quite similar but the variation 
(range) was great. The difference in variability is obviously due to a grinding process that 
breaks up the delicate tube structure of the drug-loaded MSFs resulting in plate like 
particles (Fig. 3A2). The difference in the pore size of the intact blank MSFs and the 
respective powder sample can be explained by opening of the closed and bottle-like pores 
due to grinding.  
 
Sorbed water can act as (1) a direct reactant (hydrolytic reactions), (2) a chemical 
reactivity inhibitor (Maillard reaction), (3) a solvent system, and (4) an external 
plasticizer (Shalaev and Zografi, 1996). In our system, water acted as a plasticizer, thus 
reducing the viscosity of the melt and improved the performance of a MES. The 
plasticizing effect of water has been previously shown for starches prior extrusion into 
the foams (Shogren, 1996; Sjöqvist and Gatenholm, 2005). In the case of starch 
extrusion, water added in the system is entrapped inside the cavities of the extrudate, and 
after leaving extruder, it evaporates and forms channels in the matrix (Miladinov and 
Hanna, 1999). It is evident that similar interaction with water also occurs in the present 
MES process, thus resulting in the formation of partially hollow MSF structures.  
 
3.5 Physical solid state and drug-carrier interactions  
 
The XRPD was used to detect the potential physical solid-state changes of the 
components in a MES process. As shown in Fig. 4, the drug (IND) in the PM1 preserved 
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its γ-IND crystalline form after mixing with SOL (a slightly elevated baseline of 
amorphous SOL can be also seen). As expected, the PM of amorphous IND and SOL 
(PM2) showed only an amorphous halo. In case of PM3 (the PM was stored at RH 90%), 
the XRPD pattern showed minor intensity changes, but the γ-IND reflections were clearly 
distinguishable. The polymorphic transformation of an amorphous IND to α-IND at such 
a high RH reported in literature (Savolainen et al., 2007) was not detected in this study. 
Evidently the addition of polymer (SOL) can significantly alter the crystallization 
behavior of an amorphous material. The MSFs of IND and SOL (originated from the 
PM3) showed the XRPD pattern with a clear amorphous halo, thus confirming the 
formation of an amorphous SD (Fig. 4). 
     
 
 
Figure 4. X-ray powder diffraction (XRPD) patterns of starting materials, physical 
mixtures (PMs) and melt-electrospun fibers (MSF). Key: γ-IND – indomethacin, SOL – 
Soluplus®, PM1 – the physical mixture of crystalline γ-IND and SOL at the weight ratio 
1:3 (drug:polymer), PM2 – the physical mixture of amorphous IND and SOL at the 
weight ratio 1:3 (drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-
electrospun fibers prepared from PM3. All patterns are normalized and off-set for clarity. 
 
FTIR spectroscopy was used to investigate the potential drug-carrier polymer 
interactions during MES. In our study, a special attention was paid to the region between 
1650 and 1750 cm-1 which is characteristic to IND carbonyl (C=O) stretching bands 
(Ewing et al., 2014). As seen in Fig. 5, the FTIR spectrum of γ-IND contains two bands 
in this region. The peaks at 1688 cm-1 and 1711 cm-1 were assigned to the benzoyl C=O 
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and assymetric stretch of the carbocylic acid bands, respectively. The present results are 
in accordance with the wavenumbers reported for C=O bands in the literature (Ewing et 
al., 2014; Lin et al., 2015; Terife et al., 2012). The spectra of PM1 and PM3 are quite 
similar. Both contain the benzoyl C=O vibration band at 1688 cm-1. Due to spectral 
overlapping with the SOL ester C=O band at 1732 cm-1, the band assigned to the 
assymetric stretch of the carbocylic acid is located at 1715 cm-1 in the spectra of PM1 
and PM3. The benzoyl C=O vibration band appears at 1682 cm-1 in the spectra of MSFs 
and PM2. According to the literature, the band at this wavenumber is specific to 
amorphous IND (Ewing et al., 2014; Lin et al., 2015; Terife et al., 2012). The spectrum 
of PM2 contains a shoulder to the SOL ester C=O band at 1709 cm-1 that has been 
assigned to hydrogen bonded carbocylic acid C=O in amorphous IND molecules 
arranged as chains or dimers in the literature (Ewing et al., 2014; Lin et al., 2015; Terife 
et al., 2012). This feature is lacking in the spectrum of MSFs. This difference in the 
spectra could indicate at least partial hydrogen bonding between IND and SOL molecules 
in MSFs. 
  
 
Figure 5. Fourier Transform Infrared (FTIR) spectra of starting materials, physical 
mixtures (PMs) and melt-electrospun fibers (MSF) Key: γ-IND – indomethacin, SOL – 
Soluplus®, PM1 – the physical mixture of crystalline γ-IND and SOL at the weight ratio 
1:3 (drug:polymer), PM2 – the physical mixture of amorphous IND and SOL at the 
weight ratio 1:3 (drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-
electrospun fibers prepared from PM3. All patterns are normalized and off-set for clarity. 
 
3.6 1H and 13C FT-NMR spectroscopy 
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1H-spectra of PM1 and MSFs were recorded after dissolving the materials in 
deuterochloroform. The chemical shifts of the IND and SOL coincided for the two 
mixtures and no signs of thermal degradation were observed for the electrospun mixture 
(Fig. 6A).  
 
 
Figure 6. Overlay of 1H-spectrum of physical mixture (PM) and melt-electrospun fibers 
(MSFs) (A) and 13C CP-MAS-spectra of starting materials, physical mixtures (PMs) and 
melt-electrospun fibers (MSF) (B). Key: γ-IND – indomethacin, SOL – Soluplus®, PM1 
– the physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 
(drug:polymer), MSF – melt-electrospun fibers prepared from PM3 (the PM1 stored at 
high RH (90%). 
 
13C FT-NMR spectroscopy (13C CP-MAS-spectra) results are shown in Fig. 6B. 13C-CP-
MAS-spectrum of the PM1 shows the chemical shifts of both substances as a direct 
superposition of the spectra of the pure materials. In the PM1, IND is still in the γ-form 
as indicated by the lack of splitting of the signals as reported previously (Masuda et al., 
2006). For the MSFs, the chemical shifts show a marked change as in general the signals 
from γ-IND are broadened significantly and nearby signals are merged together. As the 
signals from the pure SOL are already quite broad, similar changes were not observed 
for SOL in MSFs. This change in the IND spectra can be considered as an indication of 
more intimate mixing of the substances during a MES process.  
 
In order to get more information about the difference of IND in the PM1 and MSFs, the 
T1(1H) was recorded for solid state samples using the inversion recovery technique and 
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the relaxation delay was varied from 0.500 to 200 s. For mixtures with small domain 
sizes spin diffusion results in just one T1(1H), i.e. magnetization in the regions that would 
otherwise have longer T1(1H) diffuses into regions with shorter T1(1H). It has been 
shown in a previous study (Brettmann et al., 2012), that equation 1 can be used to 
calculate the approximate domain sizes. 
 
L = (6DTi)1/2    Eq. 1 
 
In the Eq. 1, L is the magnetization diffusion length, D is the spin diffusion coefficient 
and Ti is the relaxation time. In this study, approximate values of D, 8.0×10-16 m2/s for 
rigid systems and 0.5×10-16 m2/s for mobile systems were used, which were reported 
earlier by Spiegel et al. (1994). Because the rigidity/flexibility of the system is not 
precisely known we present the domain sizes as a range and the result gives upper limits 
for the domain size. To avoid the possible overlapping of the signals, inversion recovery 
of only two regions were followed. Signals in the approximate region of 63-76 ppm 
originate exclusively from SOL and 125-138 ppm from IND. The measured T1(1H) of 
SOL (63-76 ppm) is 2.061 s for the PM1 and 2.067 s for the MSFs, and they can be 
considered to be practically the same. However, the measured T1(1H) of IND (125-138 
ppm) in the PM1 is 4.524 s compared to that of 2.165 s for the MSFs. This gives IND a 
domain size range of 25-100 nm for the MSFs. The very similar values of T1(1H) for 
both IND and SOL in the MSFs can be considered as a strong indication of significantly 
smaller domain size of the IND in the SOL matrix compared to the PM1. The T1ρ1H, 
which would give information about the domain size within the range of 2-20 nm, were 
not measured as the long spin-lock times would have seriously damaged the probe.  
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3.7 Dissolution  
 
In our study, the powder samples prepared form intact MSFs were subjected to in-vitro 
drug release studies. The dissolution rate of MSFs and PM2 (amorphous IND) was 
significantly higher than that of crystalline γ-IND powder (Fig. 7). The PM1 showed the 
slowest drug release, probably due to the gel formation of the polymer (SOL). Such 
observation is consistent with the previous findings (Terife et al., 2012). Almost complete 
drug release from MSFs was observed within 30 min (88.7±0.5%), while the amount of 
drug released from the corresponding PM1 and PM2 at the same time point of the 
experiment was only 16.1±1.1% and 38.1±5.7%, respectively. It is well-known that 
amorphous IND has nearly 1.4 fold higher solubility in water compared to its crystalline 
form (Imaizumi et al., 1980; Hancock and Parks, 2000). The improved release rate of 
IND from MSFs is evidently due to amorphous state and smaller domain size of IND 
compared to PM1 and PM2. Furthermore, MSFs in a powder form provide a higher 
effective surface area compared to other solid state forms. This is due to a specific 
morphology of the powder particles obtained by grinding the present MSFs (i.e., partially 
plate shaped particles). These properties have been reported to have an significant effect 
on the release rate of a poorly water-soluble drugs (Hancock and Parks, 2000; Hughey et 
al., 2013; Merisko-Liversidge and Liversidge, 2011). Our results are also in accordance 
with those reported by Balogh et al. (2014) and Nagy et al. (2013), who found that the 
drug release from MSF was comparable to the fibers fabricated by solvent-based 
electrospinning (SES ) and superior to PMs and drug alone (Balogh et al., 2014; Nagy et 
al., 2013).  
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Figure 7. In vitro dissolution profiles of γ-IND, physical mixtures (PMs) and melt-
electrospun fibers (MSF) at the weight ratio 1:3 (drug:polymer) in pH 6.8 phosphate 
buffer (n=3). Key: γ-IND – indomethacin, PM1 – the physical mixture of crystalline γ-
IND and SOL at the weight ratio 1:3 (drug:polymer), PM2 – the physical mixture of 
amorphous IND and SOL at the weight ratio 1:3 (drug:polymer), MSF – melt-electrospun 
fibers prepared from PM3. The error bars indicate the standard deviations (n = 3). 
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4.  Conclusions 
 
We showed that MES is an auspicious novel method for fabricating amorphous SDs for 
poorly water-soluble drugs. The use of water in a controlled manner enabled to lower the 
MES temperature significantly through a plasticization effect and by creating additional 
pressure in a syringe. Only minimal thermal degradation of a model drug (IND) is 
associated with the fabrication of MSFs in a MES process. Solid-state analysis suggests 
more intimate mixing between IND and an amorphous stabilizing carrier material (SOL) 
in the present MSFs. The MSFs of IND and SOL provided significantly faster drug 
dissolution (within 30 min) compared to the corresponding PMs and crystalline drug. In 
summary, (1) the diameter of the present MSFs is at a micron scale; (2) the IND is 
rendered amorphous in MSF; (3) MSFs have a high surface area; (4) water as a plasticizer 
can reduce the temperature of MES process; (5) both SOL and IND remain chemically 
stable during a MES process, and (6) the dissolution of a drug (IND) is rapid from MSFs. 
Therefore, the MSFs produced by MES could be an alternative strategy in improving the 
dissolution rate, and consequently the oral bioavailability of poorly water-soluble drugs. 
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Figure captions 
 
 
Figure 1. Schematic illustration of a melt electrospinning (MES) device with a heating 
system based on oil circulating through the jacket placed around the metal syringe. Arrow 
points out circulating heated oil and the direction of the collector movement. 
 
Figure 2. Thermogravimetric analysis (TGA) (A) and differential scanning calorimetry 
(DSC) thermograms (B) of starting materials, physical mixtures (PMs) and melt-
electrospun fibers (MSF). Key: γ-IND – indomethacin, SOL - Soluplus®, PM1 – the 
physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 (drug:polymer), 
PM2 – the physical mixture of amorphous IND and SOL at the weight ratio 1:3 
(drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-electrospun fibers 
prepared from PM3. The actual process temperature of MES (180 C) is indicated with 
a solid line in the figure. 
 
Figure 3. The SEM images of (A1) intact melt-electrospun fibers (MSF) of γ-IND and 
SOL at the weight ratio of 1:3 (drug to polymer), (A2) the corresponding ground MSFs, 
(B1) blank MSFs, and (B2) the corresponding ground blank MSFs. Key: γ-IND – 
indomethacin, SOL – Soluplus®. 
 
Figure 4. X-ray powder diffraction (XRPD) patterns of starting materials, physical 
mixtures (PMs) and melt-electrospun fibers (MSF). Key: γ-IND – indomethacin, SOL – 
Soluplus®, PM1 – the physical mixture of crystalline γ-IND and SOL at the weight ratio 
1:3 (drug:polymer), PM2 – the physical mixture of amorphous IND and SOL at the 
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weight ratio 1:3 (drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-
electrospun fibres prepared from PM3. All patterns are normalized and off-set for clarity. 
 
Figure 5. Fourier Transform Infrared (FTIR) spectra of starting materials, physical 
mixtures (PMs) and melt-electrospun fibers (MSF) Key: γ-IND – indomethacin, SOL – 
Soluplus®, PM1 – the physical mixture of crystalline γ-IND and SOL at the weight ratio 
1:3 (drug:polymer), PM2 – the physical mixture of amorphous IND and SOL at the 
weight ratio 1:3 (drug:polymer), PM3 – the PM1 stored at high RH (90%), MSF – melt-
electrospun fibers prepared from PM3. All patterns are normalized and off-set for clarity. 
 
Figure 6. Overlay of 1H-spectrum of physical mixture (PM) and melt-electrospun fibers 
(MSFs) (A) and 13C CP-MAS-spectra of starting materials, physical mixtures (PMs) and 
melt-electrospun fibers (MSF) (B). Key: γ-IND – indomethacin, SOL – Soluplus®, PM1 
– the physical mixture of crystalline γ-IND and SOL at the weight ratio 1:3 
(drug:polymer), MSF – melt-electrospun fibers prepared from PM3 (the PM1 stored at 
high RH (90%). 
 
Figure 7. In vitro dissolution profiles of γ-IND, physical mixtures (PMs) and melt-
electrospun fibers (MSF) at the weight ratio 1:3 (drug:polymer) in pH 6.8 phosphate 
buffer (n=3). Key: γ-IND – indomethacin, PM1 – the physical mixture of crystalline γ-
IND and SOL at the weight ratio 1:3 (drug:polymer), PM2 – the physical mixture of 
amorphous IND and SOL at the weight ratio 1:3 (drug:polymer), MSF – melt-electrospun 
fibers prepared from PM3. The error bars indicate the standard deviations (n = 3). 
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Appendix. Near-infrared spectroscopy. 
 
Method: Near-infrared spectroscopy (NIR) spectra (1200-2200 nm) were measured with 
AvaSpec-NIR256-2.2 (Avantes, Netherlands), equipped with 256 pixel inGaAs detector 
and tungsten halogen lamp as a light source (AvaLight-HAL). A reference spectrum was 
recorded with a Teflon background. The spectra were collected from 1100 to 2200 nm 
with a 30 ms integration time and the number of averaged scans per spectrum was 4. 
Each sample was measured in pentaplicate. Standard normal variate (SNV) correction 
and mean centering were used for pretreatment of the spectra. 
 
NIR spectra were used to verify the moisture sorption on the PMs of IND and SOL. It 
can be clearly seen that the PMs stored at high RH (50% and 90%) sorb more water than 
the respective PMs stored at low RH (0%)(Appendix figure). The main differences can 
be observed in the NIR spectra at wavelengths that are related with water. Spectral 
features of water are overtones and combination bands at approximately 1400 (the first 
overtone related to O-H stretching vibration) and 1900-1950 nm (combination band of 
water) (Heinz et al., 2007; Savolainen et al., 2007).  
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Appendix figure. Near-infrared (NIR) spectra of the physical mixture (PM) of 
crystalline IND and SOL at the weight ratio 1:3 (drug:polymer) stored at different RH. 
 
 
 
